Sonja Nelson - 01 Jan 2023 Form 3 Insider Report for Ambrx Biopharma Inc.

Role
Chief Fin. & Operating Officer
Signature
/s/ Sonja Nelson
Issuer symbol
N/A
Transactions as of
01 Jan 2023
Net transactions value
$0
Form type
3
Filing time
03 Jan 2023, 17:32:44 UTC
Previous filing
11 Feb 2022
Next filing
31 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AMAM Employee Stock Option (right to buy) 01 Jan 2023 Ordinary Shares 2,574,596 $2.56 Direct F1, F2
holding AMAM Employee Stock Option (right to buy) 01 Jan 2023 Ordinary Shares 850,000 $0.6400 Direct F2, F3
holding AMAM Employee Stock Option (right to buy) 01 Jan 2023 Ordinary Shares 425,000 $0.6400 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent of the Ordinary Shares subject to the option vested on June 30, 2022, and the remainder vests in thirty-six equal monthly installments following such date.
F2 The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents seven Ordinary Shares of the Issuer.
F3 Twenty-five percent of the Ordinary Shares subject to the option vests on February 23, 2023, and the remainder vests in thirty-six equal monthly installments following such date.